search
Back to results

Butorphanol in Pain Following Ablation for Hepatic Tumor

Primary Purpose

Visceral Pain, Microwave Ablation, Hepatic Tumor

Status
Completed
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Butorphanol
normal saline
Sponsored by
Bibo Wang
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Visceral Pain

Eligibility Criteria

20 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: patients performing Microwave Ablation sign the informed consent Exclusion Criteria: Patients with a body mass index > 30 kg/m2 a history of depression opioid dependence poorly controlled hypertension (systolic blood pressure > 180 mmHg) myocardial infarction severe liver disease significant abdominal pain before surgery patients with sensory system or language dysfunctions who could not cooperate to complete the scale pregnant women.

Sites / Locations

  • Jinling Hosipiatl

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Butorphanol

normal saline

Arm Description

Outcomes

Primary Outcome Measures

Visceral Pain
VAS score of visceral pain

Secondary Outcome Measures

Visceral Pain
VAS score of visceral pain

Full Information

First Posted
August 29, 2023
Last Updated
September 2, 2023
Sponsor
Bibo Wang
Collaborators
Eastern Hepatobiliary Surgery Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT06031129
Brief Title
Butorphanol in Pain Following Ablation for Hepatic Tumor
Official Title
Effectiveness of Butorphanol in Alleviating Postoperative Visceral Pain Following Microwave Ablation for Hepatic Tumor: A Multicentral, Randomized, Placebo-Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Completed
Study Start Date
March 1, 2023 (Actual)
Primary Completion Date
July 30, 2023 (Actual)
Study Completion Date
August 9, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Bibo Wang
Collaborators
Eastern Hepatobiliary Surgery Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No

5. Study Description

Brief Summary
The objective of this investigation was to evaluate the influence of Butorphanol on postoperative pain mitigation in patients undergoing microwave ablation for hepatic tumor. Employing a rigorously designed multicentral, randomized, and placebo-controlled format, patients subjected to microwave ablation were assigned randomly to either Butorphanol (experimental group) or normal saline (control group). Primary outcomes encompassed intraoperative pain levels assessed through patient-driven evaluation utilizing a 10-point visual analog scale (VAS). Secondary outcomes included postoperative pain levels at the 6-hour mark (VAS) and comprehensive pain assessment outcomes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Visceral Pain, Microwave Ablation, Hepatic Tumor

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
300 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Butorphanol
Arm Type
Experimental
Arm Title
normal saline
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Butorphanol
Intervention Description
The pharmacological attributes of Butorphanol, characterized by its mild impact on cardiopulmonary dynamics and demonstrated efficacy in attenuating mechanical traction-induced discomfort, culminate in an ameliorative effect on postoperative nausea and vomiting rates. Importantly, it substantively attenuates visceral postoperative pain. However, sedation can also cause dizziness, drowsiness, and other adverse reactions during recovery
Intervention Type
Drug
Intervention Name(s)
normal saline
Intervention Description
normal saline contain 0.9% NaCl sodium.
Primary Outcome Measure Information:
Title
Visceral Pain
Description
VAS score of visceral pain
Time Frame
during the surgery
Secondary Outcome Measure Information:
Title
Visceral Pain
Description
VAS score of visceral pain
Time Frame
6-hour after surgery

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: patients performing Microwave Ablation sign the informed consent Exclusion Criteria: Patients with a body mass index > 30 kg/m2 a history of depression opioid dependence poorly controlled hypertension (systolic blood pressure > 180 mmHg) myocardial infarction severe liver disease significant abdominal pain before surgery patients with sensory system or language dysfunctions who could not cooperate to complete the scale pregnant women.
Facility Information:
Facility Name
Jinling Hosipiatl
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
200000
Country
China

12. IPD Sharing Statement

Learn more about this trial

Butorphanol in Pain Following Ablation for Hepatic Tumor

We'll reach out to this number within 24 hrs